Actively Recruiting
Randomized Study Evaluating Safety, Tolerability, and Preliminary Effects of SGC001 Injection in Adults with Predicted Severe Acute Pancreatitis
Led by Beijing Sungen Biomedical Technology Co., Ltd · Updated on 2026-10-13
129
Participants Needed
15
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients at high risk of developing severe acute pancreatitis to evaluate the safety, tolerability, biological effects, and preliminary efficacy of a study drug called SGC001. This early phase clinical trial includes a dose escalation phase focused on safety and tolerability, followed by a dose exploration phase assessing efficacy. Participants receive the study drug or a placebo alongside standard care to compare outcomes. Participants receive a single intravenous infusion of either SGC001 or a placebo. In Part A, doses of 300mg or 600mg are given, with possible adjustments based on safety reviews. Part B uses one or two selected optimal doses from Part A findings. Each infusion lasts about 60 minutes and is administered as an add-on to standard treatment for predicted severe acute pancreatitis. During the study, participants are monitored for safety, including adverse events over 85 days in Part A, and clinical efficacy, such as days alive without organ failure or systemic inflammatory response syndrome SIRS within 14 days in Part B. Researchers will perform assessments to track biological and pharmacological responses. The study runs from screening through treatment and follow-up, with overall participation lasting several months to capture safety and preliminary effectiveness data.
CONDITIONS
Brief Title
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
Research Team
L
Lily Shi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here